The Registry of Oncology Outcomes Associated with Testing and Treatment

CompletedOBSERVATIONAL
Enrollment

167

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
AdenocarcinomaAdenocystic CarcinomaAnal CancerAppendix CancerBrain TumorGlioblastomaAstrocytomaBile Duct CancerCholangiocarcinomaBladder CancerBone CancerSynovial SarcomaChondrosarcomaLiposarcomaSarcoma, KaposiSarcoma,Soft TissueSarcomaOsteosarcomaCNS CancerBrain Stem NeoplasmsBreast CancerCervical CancerColorectal CancerRectal CancerColon CancerEsophageal CancerEsophagus CancerCancer of ColonPancreatic CancerCancer of PancreasTestis CancerTesticular CancerUreter CancerRenal Cell CarcinomaKidney CancerGestational Trophoblastic TumorHead and Neck NeoplasmsParotid TumorLarynx CancerTongue CancerPharynx CancerSalivary Gland CancerAcute Myeloid LeukemiaChronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaMultiple MyelomaNon Hodgkin LymphomaCarcinoid TumorLung CancerNeuroendocrine TumorsMesotheliomaThyroid CancerParathyroid NeoplasmsAdrenal CancerSmall Bowel CancerStomach CancerLiver CancerHepatic CancerMelanomaSkin CancerUnknown Primary TumorsUterine CancerFallopian Tube CancerOvarian CancerProstate CancerVaginal CancerPenile CancerVulvar CancerWaldenstrom MacroglobulinemiaCancer, AdvancedThymus CancerNasopharyngeal CarcinomaMultiple Endocrine NeoplasiaPheochromocytomaSmall Cell CarcinomaPulmonary Carcinoma
Interventions
DIAGNOSTIC_TEST

Biomarker Testing (L)

Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.

DRUG

Systemic Treatment (T)

Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.

OTHER

Patient Reported Outcomes (P)

Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.

Trial Locations (2)

78041

Oncology and Hematology of South Texas, Laredo

83404

Teton Cancer Institute, Idaho Falls

All Listed Sponsors
lead

Taproot Health

INDUSTRY